Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 51

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 51
---
 and efficacy to the FDA and other regulators, safety or efficacy concerns in the medical community may hinder market acceptance. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources, including management time and financial resources, and may not be successful. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:

| ● | the efficacy and safety of the product as demonstrated in pivotal clinical trials; |

| ● | the potential and perceived advantages of the product compared to competitive and alternative therapies; |

| ● | the prevalence and severity of any side effects; |

| ● | whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy; |

| ● | our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices; |

| ● | the product’s convenience and ease of dosing and administration compared to alternative treatments, including the need to have products administered in clinical settings, rather than the home, for patients who are prescribed the products; |

| ● | the willingness of the target patient population to try, and of physicians to prescribe, the product;             |
| ● | limitations or warnings, including distribution or use restrictions contained in the product’s approved labeling; |

| ● | the strength of sales, marketing and distribution support; |

| ● | restrictions on how the product is distributed; |

| ● | the timing of market introduction of competitive products; |

31

| ● | publicity concerning these products or competing products and treatments; |

| ● | changes in the standard of care for the targeted indications for the product; and |

| ● | availability and adequacy of coverage and reimbursement from government payors, managed care plans and other third-party payors. |

Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians’ organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that any of our products is safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidates we develop do not achieve an adequate level of acceptance, they may